Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 9/20 | 0.51 |
| ▸ | CDK2 | P24941 | 8/20 | 0.51 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.39 |
| ▸ | KCNN3 | Q9UGI6 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13120621 | 0.90 | CDK2 (0.65) | GSK3BCDK2CCNA2CCNA1CCNE1 | |
| SCHEMBL13289375 | 0.90 | CDK2 (0.54) | GSK3BCDK2CCNA2CCNA1KCNN3 | |
| SCHEMBL13289338 | 0.88 | GSK3B (0.47) | GSK3BCDK2CCNA2CCNA1MEN1 | |
| SCHEMBL13288974 | 0.86 | CDK2 (0.52) | GSK3BCDK2CCNA2CCNA1MEN1 | |
| SCHEMBL12954278 | 0.86 | CDK2 (0.52) | GSK3BCDK2CCNA2CCNA1MEN1 | |
| SCHEMBL13289242 | 0.86 | GSK3B (0.46) | GSK3BCDK2CCNA2CCNA1MEN1 | |
| SCHEMBL13289430 | 0.85 | GSK3B (0.49) | GSK3BCDK2CCNA2CCNA1KCNN3 | |
| SCHEMBL13120656 | 0.85 | CDK2 (0.69) | GSK3BCDK2CCNA2CCNA1CCNE1 | |
| SCHEMBL13289431 | 0.85 | CDK2 (0.49) | GSK3BCDK2CCNA2CCNA1KCNN3 | |
| SCHEMBL13288973 | 0.84 | CDK2 (0.48) | GSK3BCDK2CCNA2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2194058-A1 | Pyrazolopyrimidines suitable for the treatment of cancer diseases | SCHERING CORPORATION (US) | 2010-06-09 | — | — | EP | disclosed |